<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37030518</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1916-7075</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Canadian journal of cardiology</Title><ISOAbbreviation>Can J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Considerations in the Management of People With Suspected Long COVID.</ArticleTitle><Pagination><StartPage>741</StartPage><EndPage>753</EndPage><MedlinePgn>741-753</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjca.2023.04.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0828-282X(23)00303-3</ELocationID><Abstract><AbstractText>Approximately 15% of adult Canadians with SARS-CoV-2 infection develop lingering symptoms beyond 12 weeks after acute infection, known as post-COVID condition or long COVID. Some of the commonly reported long COVID cardiovascular symptoms include fatigue, shortness of breath, chest pain, and palpitations. Suspected long-term cardiovascular complications of SARS-CoV-2 infection might present as a constellation of symptoms that can be challenging for clinicians to diagnose and treat. When assessing patients with these symptoms, clinicians need to keep in mind myalgic encephalomyelitis/chronic fatigue syndrome, postexertional malaise and postexertional symptom exacerbation, dysautonomia with cardiac manifestations such as inappropriate sinus tachycardia, and postural orthostatic tachycardia syndrome, and occasionally mast cell activation syndrome. In this review we summarize the globally evolving evidence around management of cardiac sequelae of long COVID. In addition, we include a Canadian perspective, consisting of a panel of expert opinions from people with lived experience and experienced clinicians across Canada who have been involved in management of long COVID. The objective of this review is to offer some practical guidance to cardiologists and generalist clinicians regarding diagnostic and treatment approaches for adult patients with suspected long COVID who continue to experience unexplained cardiac symptoms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Kieran L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada; ICES, Toronto and Ottawa, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; Temmy Latner Centre for Palliative Care, Toronto, Ontario, Canada. Electronic address: kieran.quinn@sinaihealth.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Grace Y</ForeName><Initials>GY</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Alberta Respiratory Centre, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Jillian F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bh&#xe9;reur</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, Qu&#xe9;bec, Canada; School of Rehabilitation, Faculty of Medicine and Health Science, Universit&#xe9; de Sherbrooke, Research Center of the Centre Hospitalier de l'Universit&#xe9; de Sherbrooke, Sherbrooke, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Adam D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Cornerstone Physiotherapy, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Chung Wai</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Kit Yan Christie</ForeName><Initials>KYC</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowan</LastName><ForeName>Juthaporn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Clinical Epidemiology Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crampton</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Toronto Western Family Health Team, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xe9;cary</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Rehabilitation, Faculty of Medicine and Health Science, Universit&#xe9; de Sherbrooke, Research Center of the Centre Hospitalier de l'Universit&#xe9; de Sherbrooke, Sherbrooke, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Emilia L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Center for Inflammation, Immunity and Infectious Diseases, Montreal Clinical Research Institute (IRCM), Montreal, Qu&#xe9;bec, Canada; Department of Medicine, Universit&#xe9; de Montr&#xe9;al, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>Lorraine</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Person with lived experience, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Douglas P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Physical Therapy, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanneman</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada; University Medical Imaging Toronto, Peter Munk Cardiac Center, University Health Network, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Paula J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Cardiology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Sheila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Gabrielle M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parhizgar</LastName><ForeName>Parinaz</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharkawy</LastName><ForeName>Abdu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Karen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waserman</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zannella</LastName><ForeName>Vanessa E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Medicine, University Health Network, Toronto, Ontario, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Cardiol</MedlineTA><NlmUniqueID>8510280</NlmUniqueID><ISSNLinking>0828-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>Environ 15 % des adultes canadiens atteints d&#x2019;une infection &#xe0; SRAS-CoV-2 pr&#xe9;sentent des sympt&#xf4;mes qui persistent plus de 12 semaines apr&#xe8;s la phase aigu&#xeb; de l&#x2019;infection, ce qu&#x2019;on appelle le syndrome post-COVID ou la COVID longue. Certains des sympt&#xf4;mes cardiovasculaires courants rapport&#xe9;s dans les cas de COVID longue comprennent la fatigue, l&#x2019;essoufflement, les douleurs &#xe0; la poitrine et les palpitations. Les complications cardiovasculaires &#xe0; long terme pr&#xe9;sum&#xe9;es de l&#x2019;infection &#xe0; SRAS-CoV-2 pourraient se pr&#xe9;senter sous la forme d&#x2019;un ensemble de sympt&#xf4;mes difficiles &#xe0; diagnostiquer et &#xe0; traiter pour les cliniciens. Lors de l&#x2019;&#xe9;valuation des patients pr&#xe9;sentant ces sympt&#xf4;mes, les cliniciens doivent garder en t&#xea;te l&#x2019;enc&#xe9;phalomy&#xe9;lite myalgique, ou syndrome de fatigue chronique, le malaise post-effort et l&#x2019;exacerbation des sympt&#xf4;mes post-effort, la dysautonomie avec manifestations cardiaques comme une tachycardie sinusale inappropri&#xe9;e, et le syndrome de tachycardie orthostatique posturale, et parfois le syndrome d&#x2019;activation mastocytaire. Dans cette synth&#xe8;se, nous r&#xe9;sumons o&#xf9; en sont les donn&#xe9;es sur la prise en charge des s&#xe9;quelles cardiaques de la COVID longue &#xe0; l&#x2019;&#xe9;chelle mondiale. Nous incluons &#xe9;galement le point de vue de personnes avec exp&#xe9;rience v&#xe9;cue et de cliniciens d&#x2019;exp&#xe9;rience d&#x2019;un peu partout au Canada qui ont &#xe9;t&#xe9; impliqu&#xe9;s dans la gestion de la COVID longue. L&#x2019;objectif est d&#x2019;offrir une orientation pratique aux cardiologues et aux g&#xe9;n&#xe9;ralistes quant aux approches diagnostiques et th&#xe9;rapeutiques &#xe0; adopter aupr&#xe8;s des patients adultes chez qui une COVID longue est suspect&#xe9;e et qui continuent de pr&#xe9;senter des sympt&#xf4;mes cardiaques inexpliqu&#xe9;s.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>8</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37030518</ArticleId><ArticleId IdType="pmc">PMC10160565</ArticleId><ArticleId IdType="doi">10.1016/j.cjca.2023.04.003</ArticleId><ArticleId IdType="pii">S0828-282X(23)00303-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int Available at:</Citation></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Canada, Public Health Agency of Canada  COVID-19: Longer-term symptoms among Canadian adults - Highlights. https://health-infobase.canada.ca/covid-19/post-covid-condition/ Available at:</Citation></Reference><Reference><Citation>United States Census Bureau  Household Pulse Survey: Measuring Social and Economic Impacts During the Coronavirus Pandemic. https://www.census.gov/householdpulse Available at:</Citation></Reference><Reference><Citation>CDC. Centers for Disease Control and Prevention  Long COVID or Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html Available at:</Citation></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10:311&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis I., Fonseca-Rodr&#xed;guez O., Farrington P., et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8984137</ArticleId><ArticleId IdType="pubmed">35387772</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn K.L., Razak F., Cheung A.M. Assessing common and potentially modifiable symptoms of post-COVID-19 condition (long COVID) in adults. CMAJ. 2023;195:E76&#x2013;E77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9851638</ArticleId><ArticleId IdType="pubmed">36649958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., et al. A&#xa0;prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022;13:5104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Parhizgar P., Yazdankhah N., Rzepka A.M., et al. Beyond acute COVID-19: a review of long-term cardiovascular outcomes. Can J Cardiol. 2023;39:726&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9901229</ArticleId><ArticleId IdType="pubmed">36754119</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson I., Ramanathan K., Aurora R., et al. Long COVID-19: a primer for cardiovascular health professionals, on behalf of the CCS Rapid Response Team. Can J Cardiol. 2021;37:1260&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180343</ArticleId><ArticleId IdType="pubmed">34090980</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee. Gluckman T.J., Bhave N.M., et al. 2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: a report of the American College of Cardiology Solution Set Oversight Committee. J&#xa0;Am Coll Cardiol. 2022;79:1717&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926109</ArticleId><ArticleId IdType="pubmed">35307156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotler J., Holtzman C., Dudun C., Jason L.A. A&#xa0;brief questionnaire to assess post-exertional malaise. Diagnostics. 2018;8:66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6165517</ArticleId><ArticleId IdType="pubmed">30208578</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker M., Sawant H.B., Flannery T., et al. Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. J&#xa0;Med Virol. 2023;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878088</ArticleId><ArticleId IdType="pubmed">36461167</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey R., DeMars J., Franklin K., Culos-Reed S.N., Weatherald J., Wrightson J.G. Chronic fatigue and postexertional malaise in people living with long COVID: an observational study. Phys Ther. 2022;102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383197</ArticleId><ArticleId IdType="pubmed">35079817</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., Jain A.K., Meirleir K.L.D., et al. Myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome. 2011;11:7&#x2013;115.</Citation></Reference><Reference><Citation>Feigofsky S., Fedorowski A. Defining cardiac dysautonomia - different types, overlap syndromes; case-based presentations. J&#xa0;Atr Fibrillation. 2020;13:2403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7533131</ArticleId><ArticleId IdType="pubmed">33024503</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;len T., Akin C., Bonadonna P., et al. Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review. J&#xa0;Allergy Clin Immunol Pract. 2021;9:3918&#x2013;3928.</Citation><ArticleIdList><ArticleId IdType="pubmed">34166845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. Eclinicalmedicine. 2023;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;cary S., Gaboury I., Poirier S., et al. Humility and acceptance: working within our limits with long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. J&#xa0;Orthop Sport Phys. 2021;51:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">33930983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tricco A.C., Antony J., Zarin W., et al. A&#xa0;scoping review of rapid review methods. BMC Med. 2015;13:224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574114</ArticleId><ArticleId IdType="pubmed">26377409</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudski L., Januzzi J.L., Rigolin V.H., et al. Multimodality imaging in evaluation of cardiovascular complications in patients with COVID-19: JACC Scientific Expert Panel. J&#xa0;Am Coll Cardiol. 2020;76:1345&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375789</ArticleId><ArticleId IdType="pubmed">32710927</ArticleId></ArticleIdList></Reference><Reference><Citation>Khetpal V., Berkowitz J., Vijayakumar S., et al. Long-term cardiovascular manifestations and complications of COVID-19: spectrum and approach to diagnosis and management. R&#xa0;I Med J (2013) 2022;105:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">35930485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilazi M., Duffy E.Y., Thakkar A., Michos E.D. COVID and cardiovascular disease: what we know in 2021. Curr Atheroscler Rep. 2021;23:37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117457</ArticleId><ArticleId IdType="pubmed">33983522</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy M.K., Black N.A., Lamping D.L., et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2(i-iv):1&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9561895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sir William Osler aphorisms from his bedside teachings and writings. Ann Intern Med. 1950;33:1326.</Citation></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J&#xa0;Infect Dis. 2022;226:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Clinical Management of COVID-19: Living Guideline. https://app.magicapp.org/#/guideline/j1WBYn Available at:</Citation><ArticleIdList><ArticleId IdType="pubmed">35917394</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMars J., Brown D.A., Angelidis I., et al. What is safe long COVID rehabilitation? J Occup Rehabil. 2023;33:227&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9628454</ArticleId><ArticleId IdType="pubmed">36315323</ArticleId></ArticleIdList></Reference><Reference><Citation>Parotto M., Myatra S.N., Munblit D., Elhazmi A., Ranzani O.T., Herridge M.S. Recovery after prolonged ICU treatment in patients with COVID-19. Lancet Respir Med. 2021;9:812&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280055</ArticleId><ArticleId IdType="pubmed">34273267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W., Wang C.Y., Wang S.I., Wei J.C.C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. Eclinicalmedicine. 2022;53</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Sudry T., Flaks-Manov N., et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller M.C., Liang C.J., Marques A.R., et al. A&#xa0;longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. 2022;175:969&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj S.R., Guzman J.C., Harvey P., et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020;36:357&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">32145864</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpkin A.L., Vyas J.M., Armstrong K.A. Diagnostic reasoning: an endangered competency in internal medicine training. Ann Intern Med. 2017;167:507&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">28892818</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabi D.M., McBrien K.A., Sapir-Pichhadze R., et al. Hypertension Canada&#x2019;s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36:596&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">32389335</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman B.P. Evaluation of postural tachycardia syndrome (POTS) Autonomic Neurosci. 2018;215:12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">29705015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hira R., Baker J.R., Siddiqui T., et al. Objective hemodynamic cardiovascular autonomic abnormalities in post-acute sequelae of COVID-19. Can J Cardiol. 2023;39:767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9733966</ArticleId><ArticleId IdType="pubmed">36509178</ArticleId></ArticleIdList></Reference><Reference><Citation>Natelson B.H., Brunjes D.L., Mancini D. Chronic fatigue syndrome and cardiovascular disease. JACC state-of-the-art review. J&#xa0;Am Coll Cardiol. 2021;78:1056&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">34474739</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavileci B., &#xd6;zdemir E., &#xd6;zdemir B., Ereren E., Cengiz M. De-novo development of fragmented QRS during a six-month follow-up period in patients with COVID-19 disease and its cardiac effects. J&#xa0;Electrocardiol. 2022;72:44&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8917010</ArticleId><ArticleId IdType="pubmed">35306293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann A., Prosch H., Zehetmayer S., et al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS One. 2021;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553152</ArticleId><ArticleId IdType="pubmed">34710097</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpal S., Tong M.S., Borchers J., et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021;6:116&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489396</ArticleId><ArticleId IdType="pubmed">32915194</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Halushka M.K., Heide R.S.V. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc Pathol. 2021;50</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583586</ArticleId><ArticleId IdType="pubmed">33132119</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann V.O., Carerj M.L., Wieters I., et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha T., Knight D.S., Razvi Y., et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42:1866&#x2013;1878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928984</ArticleId><ArticleId IdType="pubmed">33596594</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu H., Zhang N., Zheng Y., et al. Risk stratification of cardiac sequelae detected using cardiac magnetic resonance in late convalescence at the six-month follow-up of recovered COVID-19 patients. J&#xa0;Infect. 2021;83:119&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054525</ArticleId><ArticleId IdType="pubmed">33887285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zdanyte M., Martus P., Nestele J., et al. Risk assessment in COVID-19: prognostic importance of cardiovascular parameters. Clin Cardiol. 2022;45:943&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9350294</ArticleId><ArticleId IdType="pubmed">35789499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V., Flanders S.A., O&#x2019;Malley M., Malani A.N., Prescott H.C. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174:576&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J.T., Saigal A., Karia N., et al. Ongoing exercise intolerance following COVID-19: a magnetic resonance&#x2013;augmented cardiopulmonary exercise test study. J&#xa0;Am Heart Assoc. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238618</ArticleId><ArticleId IdType="pubmed">35470679</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J., Bhagaloo L., Sy E., et al. Cardiac impairments in postacute COVID-19 with sustained symptoms: a review of the literature and proof of concept. Physiol Rep. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9393908</ArticleId><ArticleId IdType="pubmed">35993433</ArticleId></ArticleIdList></Reference><Reference><Citation>Damant R.W., Rourke L., Cui Y., et al. Reliability and validity of the post COVID-19 condition stigma questionnaire: a prospective cohort study. Eclinicalmedicine. 2023;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9694932</ArticleId><ArticleId IdType="pubmed">36447641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall M.A., Dugan E., Zheng B., Mishra A.K. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q. 2001;79:613&#x2013;639. v.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751209</ArticleId><ArticleId IdType="pubmed">11789119</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe9;cary S, Dugas M, Stefan T, et&#xa0;al. Care models for long COVID: a rapid systematic review. MedRxiv. Available at: doi:10.1101/2021.11.17.21266404. Accessed January 25, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21266404</ArticleId></ArticleIdList></Reference><Reference><Citation>Manhas K.P., O&#x2019;Connell P., Krysa J., Henderson I., Ho C., Papathanassoglou E. Development of a novel care rehabilitation pathway for post-COVID conditions (long COVID) in a provincial health system in Alberta, Canada. Phys Ther. 2022;102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384405</ArticleId><ArticleId IdType="pubmed">35778936</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn K.L., Cheung A.M., Razak F. Treating common and potentially modifiable symptoms of post-COVID-19 condition (long COVID) in adults. CMAJ. 2023;195:E80&#x2013;E81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9851632</ArticleId><ArticleId IdType="pubmed">36649947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ormiston C.K., &#x15a;wi&#x105;tkiewicz I., Taub P.R. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm. 2022;19:1880&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9287587</ArticleId><ArticleId IdType="pubmed">35853576</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw B.H., Stiles L.E., Bourne K., et al. The face of postural tachycardia syndrome &#x2013; insights from a large cross-sectional online community-based survey. J&#xa0;Intern Med. 2019;286:438&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6790699</ArticleId><ArticleId IdType="pubmed">30861229</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q., VanGundy T.B., Shibata S., Auchus R.J., Williams G.H., Levine B.D. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension. 2011;58:167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142863</ArticleId><ArticleId IdType="pubmed">21690484</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada  COVID-19: Prevention and Risks. https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks.html Available at:</Citation></Reference><Reference><Citation>Moulson N., Connelly K.A., Dorian P., et al. COVID-19, inflammatory heart disease, and vaccination in the athlete and highly active person: an update and further considerations. Can J Cardiol. 2022;38:1580&#x2013;1583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132493</ArticleId><ArticleId IdType="pubmed">35643383</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency  The Effectiveness of Vaccination against Long COVID. https://www.icpcovid.com/sites/default/files/2022-02/Ep%20241-9%20UK%20Health%20Security%20Agency%20The%20effectiveness%20of%20vaccination%20against%20long%20COVID%20Feb%202022.pdf Available at:</Citation></Reference><Reference><Citation>Simon M.A., Luginbuhl R.D., Parker R., MedRxiv  Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and up to 12 Weeks After. https://www.medrxiv.org/content/10.1101/2021.11.17.21263608v1 Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bermingham C., Pouwels K.B., et al. Changes in the trajectory of long covid symptoms following COVID-19 vaccination: community-based cohort study. BMJ. 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Agency of Canada  Evidence Brief on the Associations and Safety of COVID-19 Vaccination and Post COVID-19 Condition. https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases/2019-novel-coronavirus-infection/canadas-reponse/summaries-recent-evidence/evidence-brief-associations-safety-covid-19-vaccination-post-condition-update-2.pdf Available at:</Citation></Reference><Reference><Citation>Science Table. Quinn K.L., Katz G.M., Bobos P., et al.  Understanding the Post COVID-19 Condition (Long COVID) in Adults and the Expected Burden for Ontario. https://covid19-sciencetable.ca/sciencebrief/understanding-the-post-covid-19-condition-long-covid-in-adults-and-the-expected-burden-for-ontario/ Available at:</Citation></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz D, et&#xa0;al. Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of long Covid over 10-month follow-up. MedRxiv. Available at: doi:10.1101/2022.12.21.22283753. Accessed January 17, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.21.22283753</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. MedRxiv. 2023 doi:10.1101/2022.11.03.22281783 Available at:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.03.22281783</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the REMAP-CAP Investigators. Florescu S., Stanciu D., et al. Long-term (180-Day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857594</ArticleId><ArticleId IdType="pubmed">36525245</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>